When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.

The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.

But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.

Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.

BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.

Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.

Why Men Are at Higher Risk?

Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.

Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.

A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."

Cancer Types Most Linked to Abdominal Fat

The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.

For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.

What This Means for Men's Health and Cancer Prevention?

With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.

How To Reduce Cancer Risk In Men?

Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).

Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.

Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.

Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.

Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.

Six unvaccinated people, including children, have died from measles in the US this year. As of October 8, the country had reported 4,080 confirmed cases, according to the Centers for Disease Control and Prevention (CDC).

Measles spreads easily through the air and can remain infectious for up to two hours. Symptoms include high fever, cough, runny nose, red, watery eyes, and a rash that typically starts on the face. Infected people can spread the virus before the rash appears.

Two doses of the measles, mumps, and rubella (MMR) vaccine are approximately 97% effective against measles and remain the best protection against the disease and its complications.

Measles Can Cause Complications Years Later

Also read: Sixth Measles-Associated Death Reported In Pennsylvania As Cases Cross 1,100

Measles also causes pneumonia, brain inflammation, and death. Some complications emerge weeks or years after the initial infection.

Three serious consequences are acute disseminated encephalomyelitis (ADEM), immune amnesia, and subacute sclerosing panencephalitis (SSPE).

According to the CDC, one to three out of every 1,000 children with measles die from respiratory and neurological complications.

ADEM: When the Immune System Attacks the Brain

An 18-year-old from Mifflin County, Pennsylvania, died from acute disseminated encephalomyelitis (ADEM), reported as the state's fourth measles-associated death this year.

ADEM causes inflammation in the brain and spinal cord when the immune system mistakenly attacks nervous system tissue. It can develop weeks after infections such as measles or influenza.

Symptoms include weakness, confusion, vision problems, and seizures. Severe cases can be fatal.

ADEM occurs in approximately one out of every 1,000 measles cases. Treatment may include steroids, intravenous immunoglobulin, and plasma exchange.

Most patients recover, but lasting problems can include motor weakness, cognitive impairment, seizures, and vision loss. In a 2022 study of 77 children with moderate to severe ADEM, nearly a quarter had persistent health issues.

Immune Amnesia: Measles Can Erase Immune Memory

Read More: Measles Cases Are Rising in US—Who Should Get A Booster Shot?

Measles can destroy immune cells that remember previously encountered pathogens, weakening protection built through past infections and vaccinations. This is known as immune amnesia.

“Immune amnesia basically destroys your immune system,” said Dr. Stephen J. Elledge, professor of genetics and medicine at Harvard Medical School. “It infects and kills the cells that store immune memories — plasma cells, B cells, and T cells. It’s like burning down a library full of immunological knowledge.”

A 2019 study published in Science, co-authored by Elledge, found that measles could erase up to 73% of a person's antibody repertoire.

This loss can leave people vulnerable to infections their immune systems had previously learned to fight. Research published in 2015 suggested that rebuilding immune protection can take two to three years.

SSPE: A Fatal Disease That Can Emerge Years Later

Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological disease caused by a persistent measles virus infection in the central nervous system.

SSPE is "the most enigmatic and terrifying consequence of measles", Andrew Pavia, MD, a pediatric infectious disease epidemiologist at the University of Utah, told CIDRAP News.

Symptoms may appear seven to 10 years after measles, even in people who initially recover. Early signs include personality changes, mood swings, and headaches. The disease can progress to involuntary movements, seizures, vision loss, cognitive decline, coma, and death.

There is no known cure, and SSPE is ultimately fatal.

Infants Face a Higher SSPE Risk

Children who contract measles during infancy face a particularly high risk of SSPE.

The CDC estimated that seven to 11 out of every 100,000 people infected during the US measles resurgence of 1989–1991 were at risk of developing the disease.

A 2016 review of California health records estimated that SSPE occurred in approximately one out of every 609 children who contracted measles before 12 months of age.

A child in Los Angeles died of SSPE last year after contracting measles as an infant, before becoming eligible for the MMR vaccine. In the United States, the first dose is generally recommended at 12 to 15 months.

With measles cases continuing to rise, Pavia warned that SSPE "is a potential time bomb."

The increasing popularity of GLP-1 medications is making its way onto college campuses, where young women face growing pressure to meet ideals of thinness and beauty.

Media reports suggest that the use of GLP-1 drugs, including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), is rising among young women, including those with normal BMIs, seeking to achieve a thinner appearance.

Originally developed to treat type 2 diabetes, with some also approved for weight management, these medications can be highly effective but require a prescription and appropriate medical monitoring. Using them without a medical indication may expose people to unnecessary health risks, an expert warned.

Jay Campbell, a longevity and peptide expert and bestselling author, said

that while these drugs were developed to address metabolic conditions, they have been “hijacked as a cosmetic shortcut.”

“For someone who's metabolically dysregulated, they are a genuine medical intervention,” he told Fox News Digital. “But to a 20-year-old sorority member with a normal BMI, they look like an aesthetic hack in a syringe.”

GLP-1 Drugs Gain Attention Among College Girls

Also read: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth

A 2024 analysis published in JAMA found that 162,439 young adults ages 18 to 25 received at least one dispensed GLP-1 prescription in 2023.

Women accounted for 76.4% of these patients, although the analysis included medications prescribed for both diabetes and weight management.

Separately, the 2025 Monitoring the Future survey found that 2% of students in grades 8, 10 and 12 reported using a prescription GLP-1 medication, while another 2% said they had used one without a prescription.

Sororities can amplify pressure to maintain a certain appearance, with social media and comparisons among members potentially encouraging interest in GLP-1 drugs. Campbell said rapid, visible weight loss can quickly become a talking point within sorority houses, prompting other young women to consider the drugs as a shortcut to achieving a thinner look, including those with normal BMIs.

Risks of Using GLP-1 Drugs for Cosmetic Weight Loss

College-aged women may already be vulnerable to body-image pressures, Campbell noted, and social media can intensify those concerns.

GLP-1 medications can offer substantial benefits to eligible patients. In clinical studies of people taking these medications for obesity, fat mass generally accounts for more of the weight lost than lean mass, Campbell pointed out.

“The peptide isn't catabolic by itself – the real risk is that a healthy 20-year-old who isn't obese has far less metabolic and muscular reserve to lose from in the first place.”

When a young woman loses weight rapidly without consuming enough protein or doing resistance training, she may lose a greater proportion of lean mass, Campbell warned. Rapid weight loss can also contribute to facial and body changes sometimes referred to as “Ozempic face” and “Ozempic body.”

Read More: WHO Cautions Against GLP-1s As First-Line Treatment For Childhood Obesity, Prioritises Lifestyle Changes

5 Things To Know Before Using GLP-1 Drugs

1. Check if you need them: Consult a doctor to determine whether GLP-1 treatment is medically appropriate.
2. Protect muscle mass: Eat enough protein and include resistance training to help preserve muscle during weight loss.
3. Understand pregnancy risks: Semaglutide labeling advises stopping Wegovy at least two months before a planned pregnancy. Tirzepatide can reduce oral contraceptive effectiveness for four weeks after starting treatment and after each dose increase.
4. Monitor mental health: Discuss any history of eating disorders, anxiety or depression with your prescriber and report worsening symptoms.
5. Consider long-term safety: Discuss potential risks, side effects and ongoing monitoring with a qualified doctor before starting treatment.

An unexplained blood clot could sometimes be the first warning sign of underlying cancer. In such cases, doctors investigate beyond the immediate causes of thrombosis.

While blood clots are mostly caused after surgery, prolonged immobility and other risk factors, a clot that develops without a known trigger may need a closer look, especially in older adults or patients with other certain concerning symptoms.

On World Thrombosis Day, observed on October 13, experts talk about the importance of recognising unusual clotting patterns and investigating underlying conditions without subjecting every patient to unnecessary tests.

“Sometimes an unexplained blood clot is the first clinical sign of an underlying cancer,” Dr Rahul Bhargava, Principal Director and Chief of Hematology, Hemato Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute (FMRI), Gurugram told HealthandMe.

Can Cancer Trigger Blood Clots?

Cancer can interfere with the body's normal clotting mechanisms. Dr Bhargava explained, “Some tumors are able to activate the body’s clotting system by releasing substances such as tissue factor, which stimulates the production of thrombin and fibrin, the proteins involved in clot formation.”

He added that inflammation related to cancer and changes to blood vessels contribute to hypercoagulability, a condition in which the blood has an increased tendency to clot. In some patients, a tumour may also compress blood vessels, slowing blood flow. Cancer treatments, including surgery and certain chemotherapy drugs, can further increase the risk.

Dr Narendra Agrawal, Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute and Research Centre, explained to us that the body's natural anticoagulants help maintain blood in a liquid state. When these protective mechanisms are deficient, whether due to congenital mutations or other reasons, the risk of clotting can increase.

“When cancer is present in the body, it acts as a major driver of abnormal clotting within the vessels, making an unprovoked clot a critical clinical indicator that a malignancy may be forming,” he said.

However, an unexplained clot does not necessarily mean a person has cancer. Doctors must evaluate the patient's symptoms, medical history and other risk factors before deciding whether investigations are warranted.

Also read: Menopause Abruptly Shifts Bones, Liver And Blood Fats, Study Finds

Key Warning Signs

The absence of a clear trigger is a red flag that should not be ignored. Doctors typically look for common causes like recent surgery, trauma, prolonged immobility or long-distance travel before investigating other possibilities.

Dr Bhargava said concern increases when thrombosis occurs without an identifiable cause, particularly in older adults, or when a clot recurs despite adequate treatment. Other warning signs include unexplained weight loss, chronic fatigue, poor appetite, bleeding and changes in bowel movements.

“There is no particular symptom which will allow to distinguish cancer-associated thrombosis from others,” he cautioned, emphasising the need for a comprehensive clinical assessment rather than assuming that every unexplained clot indicates malignancy.

Dr Agrawal also highlighted specific findings that may prompt further investigation. “We suspect an underlying cancer when we encounter specific red flags,” he said, referring to unprovoked clots in older patients and physical findings like lumps, non-healing ulcers, recurring abdominal pain or blood in the stool.

Abnormal blood counts can provide additional clues. Changes in haemoglobin, white blood cell counts or platelet levels may lead doctors to investigate possible blood-related cancers or other underlying conditions.

Also read: 'Humanity Can Still Act': Lancet Warns Of 17 Global Health Threats By 2100

Cancers Linked With Unexplained Blood Clots

Certain cancers come with a greater risk of venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).

“Certain cancers that predispose one to venous thromboembolism include pancreatic, lung, stomach, colorectal and ovarian cancers. Others include some forms of blood cancers,” Dr Bhargava said.

He explained that the risk varies according to the type and stage of cancer and the treatment involved. In some patients, an unprovoked clot may develop before the cancer itself is diagnosed.

The location of the clot can also influence how symptoms appear. DVT commonly affects the deep veins of the legs, causing swelling, pain and tenderness. When a clot travels to the lungs and causes a pulmonary embolism, symptoms may include chest pain and breathlessness.

Dr Agrawal said that clots in abdominal veins may cause abdominal pain, liver dysfunction, an enlarged spleen or intestinal bleeding. Clots affecting blood vessels in the brain or central nervous system may produce neurological symptoms, including paralysis. However, the location of a clot alone cannot prove if cancer is present.

Also read: High BP in Pregnancy Linked to 42,000 Maternal Deaths, 500,000+ Stillbirths, Newborn Deaths: WHO

What Investigations Are Recommended?

Doctors generally begin with a detailed medical history, physical examination and blood tests. These may include a complete blood count and assessments of kidney and liver function. Further testing depends on the clinical findings. Imaging or endoscopy may be recommended when symptoms, examination findings or blood abnormalities raise suspicion of an underlying malignancy.

Dr Bhargava cautioned against automatically subjecting every patient with unexplained thrombosis to extensive testing. “It is not always necessary to perform extensive imaging of the whole body or tumour marker testing in every patient with a clot that is unexplained and does not have any other worrying signs,” he said.

The aim is to identify cancers that warrant further investigation while avoiding unnecessary radiation exposure and incidental findings.

Dr Agrawal said doctors may use CT scans to look for hidden tumours, with MRI or PET scans considered for specific cancer evaluations. The extent of testing depends on factors such as the patient's age, clinical presentation, blood counts and physical examination findings.

When a patient has both cancer and thrombosis, doctors must manage the clot while navigating cancer treatment and the patient's risk of bleeding. “Anticoagulants are usually administered to prevent the expansion of the existing clot and the occurrence of other clots,” Dr Bhargava said.

The choice of medication, including a direct oral anticoagulant or low molecular weight heparin, depends on the patient's condition. Factors include kidney function, the possibility of gastrointestinal or urinary bleeding, drug interactions and the type of cancer treatment being administered.

Dr Bhargava explained that doctors must also consider platelet counts, planned or recent surgery, chemotherapy-related complications and active bleeding. The duration of anticoagulation is individualised and may extend beyond three to six months while the cancer and its treatment continue to pose a risk.